2. UroToday Home
  3. Center Of Excellence

Centers of Excellence

Advanced Prostate Cancer

Curated by clinicians: educational forums with videos, abstracts and conference information

Welcome Letter from the Advanced Prostate Cancer Center of Excellence Editor

Zachary Klaassen | August 22, 2024

For more than 20 years, UroToday has been THE premier online educational resource for genitourinary oncology – clinicians educating clinicians. During this time, advanced prostate cancer has been completely transformed, pa≥ particularly in the last 10+ years. Since then, we have seen (briefly) the following in advanced prostate cancer:

  • Docetaxel for mCRPC progression
  • Cabazitaxel following docetaxel for mCRPC progression
  • Radium-223 for mCRPC
  • Docetaxel + ADT for mHSPC
  • Abiraterone + prednisone for mHSPC
  • ARPIs + ADT for mHSPC
  • ARPIs + ADT for M0 CRPC
  • Enzalutamide +/- ADT for non-metastatic HSPC
  • PARP inhibitors for mCRPC
  • Radioligand therapy for mCRPC

READ MORE PREVIOUS ARTICLES

Zachary Klaassen, MD, MSc

Zachary Klaassen, MD, MSc

Dr. Klaassen is a Urologic Oncologist, Associate Professor of Urology, Residency Program Director and the Ronald W. Lewis, MD Endowed Chair for Urologic Education at Wellstar MCG Health; Georgia Cancer Center in Augusta, GA. He was born in rural Canada and grew up in Vancouver, British Columbia. Following an undergraduate degree in Molecular Biology and Biochemistry at Simon Fraser University, he attended medical school at St. George's University in Grenada, followed by clinical rotations and a research fellowship in the metro New York area. After completing his Urology residency in Augusta, he spent two years in Toronto as a Society of Urologic Oncology fellow, obtaining a Masters of Science degree from the University of Toronto in Clinical Epidemiology. He specializes in Urology, Urologic Oncology, Robotic Surgery, Minimally Invasive Surgery, and Cancer Surgery. Dr. Klaassen is interested in treating patients with urologic malignancies, including prostate, bladder, kidney, testis, and penile cancer, using both open and minimally invasive surgical techniques. His research interests include mental health and cancer survivorship, clinical epidemiology of urologic malignancies, clinical trials, and translational research on biomarkers for early cancer detection and treatment response predictors. He believes in taking the cancer journey together with his patients and their families, focusing on treating not only the cancer but also the physical and emotional side effects of diagnosis and treatment.

Videos
View All
Clinical Conversations by Experts
Combining Lutetium-PSMA with Hormonal Therapy Enhances Prostate Cancer Treatment - Louise Emmett
MMAI Score Prognostic for Overall Survival in Oligometastatic Castration-Sensitive Prostate Cancer - Phuoc Tran & Tim Showalter
Highlights in Prostate Cancer Treatment Advances from ESMO 2024 - Ursula Vogl
Olaparib Effective in BRCA2-Altered Biochemical Recurrence Post-Prostatectomy in Phase 2 Study - Catherine Handy Marshall
Epigenetic Profiling Identifies Biomarkers Predicting Resistance to AR-Targeted Therapy in mCRPC - Wilbert Zwart
ARROW Study Reveals Iodine-131 PSMA Efficacy in Advanced Cancer - Evan Yu
Metformin Study Reveals Weight Management Benefits for ADT Therapy - Silke Gillessen
Humanized Mice Reveal Role of Immune System in Prostate Cancer Therapy Efficacy - Steven Kregel
UpFrontPSMA Trial Results: Lutetium-177 PSMA-617 in Hormone-Sensitive Prostate Cancer, Journal Club - Phillip Koo & Zachary Klaassen
STAMPEDE2 Trial Explores Combination Niraparib and Abiraterone in mHSPC - Sarah Howlett & Mahaz Kayani
AR Pathway Inhibitors vs Taxanes in mCRPC ProBio Trial - Bram De Laere
ARANOTE Trial Implications for Metastatic Prostate Cancer Management, Journal Club - Rashid Sayyid & Zachary Klaassen
Advancing mHSPC Treatment Options: ARANOTE Trial Analysis - Neal Shore & Fred Saad
INSPIRE Trial Investigates Immunotherapy for Molecularly Selected Advanced Prostate Cancer - Niven Mehra
STEAP1-Targeted T-Cell Engager Demonstrates Efficacy in mCRPC Patients - William Kevin Kelly
Emerging DLL3-Targeted Therapies Demonstrate Efficacy in Neuroendocrine Prostate Cancer - Himisha Beltran
Novel Epigenomic Liquid Biopsy Detects PSMA Expression in Prostate Cancer - Jacob Berchuck
Advancements in Lutetium-PSMA Therapy for Prostate Cancer: Clinical Trials and Future Directions - Ken Herrmann
Decipher® in mHSPC: Guiding Risk Assessment and Treatment Intensification - Gerhardt Attard
First-in-Class AR Degrader Shows Promise in Castration-Resistant Prostate Cancer - Dana Rathkopf
TALAPRO-2 Analysis: Talazoparib Enzalutamide Combo in Pretreated mCRPC - Neeraj Agarwal
CONTACT-02 Trial Results: Cabozantinib Plus Atezolizumab for mCRPC - Neeraj Agarwal
PEACE 3 Trial Results Show Promise for Radium-223 and Enzalutamide in Asymptomatic mCRPC - Fred Saad
Accelerated 177Lu-PSMA-617 Protocol Tested in STAMPEDE2 - Minal Padden-Modi & Nicholas James
RAPSON Trial Explores Radium223 and Docetaxel Sequencing in mCRPC - Vincenza Conteduca
Darolutamide Improves Outcomes for mHSPC Patients in ARANOTE Trial - Fred Saad
Utilizing the Decipher® mRNA Score for Risk Stratification in mHSPC - David Morris and Ashley Ross
PEACE-3 Trial Results: Radium-223 + Enzalutamide in mCRPC - Bertrand Tombal
STAMPEDE2 SABR Trial for Oligometastatic Prostate Cancer Treatment - Hoda Abdel-Aty
UpFrontPSMA Trial: Lutetium-PSMA + Docetaxel in mHSPC - Arun Azad
T-Cell Engagers in Prostate Cancer Treatment - Neeraj Agarwal
Tumor Suppressor Gene Signature Predicts Early Progression in mHSPC - Marta Garcia de Herreros
EMBARK Trial: Age-Stratified Analysis of Enzalutamide in High-Risk Biochemically Recurrent Prostate Cancer - Neal Shore
ZZ-FIRST Trial Demonstrates High PSA Response with Combination Therapy - Joaquin Mateo
PEACE-1 Trial Reveals Key Genomic Alterations Linked to Survival in Prostate Cancer Patients - Cédric Pobel
PRINCE Trial Highlights Early Detection of Prostate Cancer Progression with PSMA PET-CT - Michael Hofman
SPLASH Trial Highlights Radiopharmaceutical Lutetium-177’s Role in Advanced Prostate Cancer Treatment - Oliver Sartor
2024 NCCN Prostate Cancer Guidelines: Updates in M1 CSPC Treatment - Rashid Sayyid & Zachary Klaassen
Advanced Prostate Cancer: Understanding Out-of-Pocket Medication Costs - Daniel Joyce
STORM Trial Examines Elective Nodal Radiotherapy in Treating Prostate Cancer Recurrence - Piet Ost
Cardiovascular Risks of ARSIs in Prostate Cancer: Meta-Analysis Findings, Journal Club - Rashid Sayyid & Zachary Klaassen
RADIOSA Trial: SBRT vs SBRT+ADT for Oligorecurrent Prostate Cancer - Giulia Marvaso
Advancing Radiopharmaceuticals: Targeting Strategies and Isotope Selection in Cancer Therapy - John Babich
Overcoming Hormone Resistance: ARV-766 in Advanced Prostate Cancer - Daniel Petrylak
PSMA PET in Prostate Cancer: Balancing Sensitivity and Clinical Relevance - Ravi Madan
PSMA-PET/CT Guided Salvage Radiotherapy: Improving Prostate Cancer Outcomes - Constantinos Zamboglou
Copper-67 (Cu-67 or 67Cu) in Cancer Therapy: Current Developments and Future Potential - Alan Taylor
Advancing Radiopharmaceuticals: From Lead-212 to Pre-Targeting Strategies - Michael Schultz
Radiopharmaceuticals and Combination Approaches in Advancing the Prostate Cancer Treatment Landscape - Philip Kantoff
Lead-212 Radiopharmaceuticals: Next Frontier in Cancer Treatment - Emanuele Ostuni
Extracellular Vesicles in Prostate Cancer: Multi-Omic Liquid Biopsy - Irene Casanova-Salas & Joaquin Mateo
2024 NCCN Guidelines: Preventing Skeletal Events in Prostate Cancer - Rashid Sayyid & Zachary Klaassen
Cell Surface Targets in mCRPC: Expression Landscape and Therapeutic Potential - Michael Haffner
PSMAfore Trial: Lutetium PSMA's Impact on mCRPC Quality of Life - Karim Fizazi
Post-Prostatectomy Care: Variability in Treatment for Lymph Node Positive Prostate Cancer - Daniel Triner
Meta-Analysis Evaluates Cardiovascular Risks of AR Inhibitors in Prostate Cancer - Omar El-Taji & Ashwin Sachdeva
VA's Million Veterans Program Reveals Crucial Genetic Data for Prostate Cancer Treatment - Bruce Montgomery
CYCLONE 2 Trial Results: Abemaciclib in Metastatic Castration-Resistant Prostate Cancer - Matthew Smith
Prostate Cancer Diversity Revealed: AR and Neuroendocrine Signatures - Yu-Wei Chen
Mental Health and Prostate Cancer in the Veterans Population - Zachary Klaassen
IMPLEMENT Study: Addressing the Underutilization of Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer - Stacy Loeb
Machine Learning Model Predicts Overall Survival in Metastatic Prostate Cancer - Ali Sabbagh
Tarlatamab Shows Encouraging Activity in Phase 1 Trial in DLL3-Positive Neuroendocrine Prostate Cancer - Rahul Aggarwal
Enzalutamide Plus 5-Alpha Reductase Inhibitors for Castrate-Sensitive Prostate Cancer: A Phase 2 Trial - Deepak Kilari
Exploring Genetic Counseling in Veterans with Advanced Prostate Cancer - Daniel Kwon
Advancing Treatment for High-Risk Biochemical Recurrence Prostate Cancer: The ARASTEP Trial - Alexander Chehrazi-Raffle
Integrating Genetic Variants and Clinical Factors for Improved Prostate Cancer Prognostication - Susan Halabi
PROMISE Criteria: Enhanced Survival Prediction in Prostate Cancer with PSMA PET - Wolfgang Fendler
hK2-Targeted Radioligand Shows Promise in Treating Advanced Prostate Cancer: Phase I Findings - Michael Morris
COBRA Trial: Evaluating 64Cu-SAR-bisPSMA PET Imaging for Prostate Cancer Detection - Phillip Koo
Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-Blind, Phase 3 Trial - Fred Saad
MMAI Model Risk Stratification for NCCN Guidelines for Low, Intermediate, and High-Risk Prostate Cancer - Neal Shore, Daniel Spratt, & Alicia Morgans
UCHL1: A Potential Biomarker and Therapeutic Target for Neuroendocrine Prostate Cancer - Tanya Stoyanova
Comparing PSMA Ligands for Prostate Cancer Imaging - Michael Hofman
Behavioral Interventions for Mitigating ADT Side Effects in Prostate Cancer - Brian Gonzalez
Hypofractionation in Prostate Cancer Radiotherapy: Balancing Efficacy and Safety - Neha Vapiwala
Escalation Strategies for Suboptimal PSA Decline in mHSPC - Mary-Ellen Taplin
Radiating the Primary Tumor in Metastatic Hormone-Sensitive Prostate Cancer - Sandy Srinivas
EMBARK Trial: Enzalutamide Monotherapy and Combination Therapy for High-Risk Biochemical Recurrence - Neal Shore
Personalizing Salvage Radiation and Hormone Therapy for Biochemical Recurrence - Daniel Spratt
COBRA Trial Shows Promise for 64Cu-SAR-bisPSMA PET in Biochemical Recurrence - Neal Shore
Prognostic and Predictive Factors in Metastatic Hormone-Sensitive Prostate Cancer - Matthew Smith
Optimizing Lutetium-PSMA Dosing in High-Volume Disease and Special Situations - Louise Emmett
Sequencing Therapies in mCRPC After Progression on Combination Treatment - Ian Davis
Managing Frail Patients with Metastatic Hormone-Sensitive Prostate Cancer - Maria De Santis
Redefining Low-Volume Metastatic Prostate Cancer in the Era of PSMA PET Imaging - Oliver Sartor
Optimal Imaging Standards for Metastatic Castration-Sensitive Prostate Cancer - Michael Morris
The EvoPAR-Prostate 01 Trial: Novel PARP Inhibitor Saruparib in mHSPC - Neeraj Agarwal
The Use of PARP Inhibitors in mCRPC with BRCA1/2 Alterations - Joaquin Mateo
Non-Invasive Detection of Neuroendocrine Prostate Cancer Through Targeted Cell-Free DNA Methylation - Himisha Beltran & Francesca Demichelis
Optimizing Salvage Radiation Therapy in Prostate Cancer: New AUA/ASTRO/SUO Guideline - Todd Morgan
Bone Health in Advanced Prostate Cancer: Findings from the STAMPEDE Trial and Hospital Episode Statistics - Noel Clarke
PEACE V (STORM) Trial: Comparing MDT vs. Elective Nodal Irradiation for Oligorecurrent Prostate Cancer - Thomas Zilli
Darolutamide Outcomes in European Patients with Metastatic Hormone-Sensitive Prostate Cancer from the ARASENS Trial - Bertrand Tombal
The Impact of the EMBARK Trial on Treatment Decisions in High-Risk Biochemical Recurrent Prostate Cancer - Neal Shore
A Phase I Trial of Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer After Brachytherapy - Beyond the Abstract
Treating Metastatic Hormone-Sensitive Prostate Cancer: Beyond Counting Metastases - Karim Fizazi
PARP Inhibitor + AR Signaling Inhibitor Combos Improve mCRPC Outcomes in Meta-Analysis - Rashid Sayyid
Alpha vs Beta Emitters in Prostate Cancer Radiopharmaceuticals: Energy, Range, and Cytotoxicity - Alan Bryce
Examining Prostate Cancer Survival Outcomes by Patient Age and Treatment Type in Patients with Metastatic Hormone-Sensitive Prostate Cancer - Alicia Morgans
Triplet Delays Further Therapy Versus Doublet in Metastatic HSPC - Neal Shore
COMBAT Trial Yields Promising Results for Bipolar Androgen Therapy Plus Nivolumab in Metastatic Castration-Resistant Prostate Cancer - Mark Markowski & Emmanuel Antonarakis
PRIMORDIUM Trial Evaluates Apalutamide Plus ADT for High Risk Biochemical Recurrence of Prostate Cancer After Prostatectomy - Boris Hadaschik
CONTACT-02 Phase III Trial Findings on Cabozantinib-Atezolizumab Combination in mCRPC - Neeraj Agarwal
Patient Selection for PSMA Radioligand Therapy - Ephraim Parent
BRCAAway Trial: Where Combination Treatment Improve Patient Outcomes in mCRPC - Daniel George
Distinct Mesenchymal Cell States Mediate Prostate Cancer Progression - Massimo Loda
ProBio Trial Demonstrates Improved Outcomes Using Biomarker-Guided Therapy Selection for Metastatic Prostate Cancer - Henrik Grönberg
Triple-Drug Therapies Usher in Sea Change for Men With High-Risk Prostate Cancer - Rashid Sayyid & Zachary Klaassen
Novel Biomarker Analysis Reveals SPOP Gene Mutation Unlocks Sensitivity to PARP Inhibitor Treatment in Metastatic Castration-Resistant Prostate Cancer - Emmanuel Antonarakis & Jacob Orme
Combination Therapy Jolts 'Exhausted' Immune Cells Awake to Attack Tumors in Patients with Metastatic Castration-Sensitive Prostate Cancer - Jessica Hawley & Aleksandar Obradovic
ENZA-p Trial Shows Promise for Enzalutamide-Lutetium Combination in Prostate Cancer - Louise Emmett
Harnessing Tumor Biology to Improve Outcomes in Advanced Hormone-Sensitive Prostate Cancer - Gerhardt Attard
Novel STEAP1 Targeted BiTE Therapy Demonstrates Early Efficacy in Phase 1 Trial - William Kevin Kelly
Shifting Clinical Trial Design Towards Improving Patient Enrollment - Michael Morris
AMG 509's Potential in Prostate Cancer Therapy - Michael Morris
Genetic Testing Reveals Treatment Opportunity and Disparity in Advanced Prostate Cancer - Colin Pritchard
Medicare Data Compares Enzalutamide and Abiraterone Outcomes in mCRPC Patients - Dan George
Sequencing Therapies in Advanced Prostate Cancer Requires Balancing Many Factors - Rana McKay
The PSMAfore Trial and its Role in Shaping Future Prostate Cancer Treatments - Oliver Sartor
Clinical Implications and Patient Care: The SNMMI Consensus on Lutetium PSMA 617 Therapy for Advanced Prostate Cancer - Heather Jacene & Oliver Sartor
Comprehensive Genomic Profiling and Treatment Patterns Across Ancestries in Advanced Prostate Cancer - Brandon Mahal
The REASSURE Trial: Long-Term Safety of Radium-223 in Advanced Prostate Cancer - Oliver Sartor
The ECLIPSE Trial: Investigating Lutetium-177 in the Pre-Chemotherapy Space in Advanced Prostate Cancer - Daniel Saltzstein
DDR and PARP Inhibition: What's the Damage? - David VanderWeele
Prospective Monitoring of Biochemical Recurrence with PSMA PET - Ravi Madan
Understanding the Potential and Challenges of Sipuleucel-T and Radium-223 in the Management of Metastatic Castration-Resistant Prostate Cancer - Sumit Subudhi
PSMA-PET Implications for Extent and Survival Outcomes in High-Risk nmCRPC: An International Study - Boris Hadaschik
Analyzing Quality of Life and Survival from CHAARTED Prostate Cancer Trial - Daniel Sentana Lledo
Primary Analysis of STARTAR: A Phase 2 Salvage Trial for High-Risk Prostate Cancer with Biochemical Recurrence - Tian Zhang
The Relationship Between a Priori Defined Prognostic Risk Groups and Overall Survival in Men with mCRPC - Susan Halabi
A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in mHSPC: A-DREAM - Atish D. Choudhury
Early Aggressive Treatment Shows Promise for Prostate Cancer Recurrence - Stephen J. Freedland
Understanding BRCA Mutations: The Pivotal Impact of the CAPTURE Study - David Olmos
The Added Value of Docetaxel in Combination with ADT and ARPI for the Treatment of mHSPC - Ursula Vogl
Navigating Salvage Radiotherapy with Insights from PSMA PET - Jeremie Calais
Unlocking Prostate Cancer Treatment: The Pathway of CAR T Targeting Prostate Stem Cell Antigen - Tanya Dorff
Integration of Lutetium into Clinical Practice: A Urologist's Perspective - Neal Shore
Promising Results: Cohort Two of TALAPRO-2 Study Reveals Insights and Potential Breakthroughs in Prostate Cancer Treatment - Karim Fizazi
Beyond BRCA-1 and 2: The Impact of the TALAPRO-2 Study on Prostate Cancer Care - Cora Sternberg
Exploring Racial Biases in Clinical Trials: The PANTHER Study's Findings on Prostate Cancer - Dan George
The Prognostic Value of PSA Levels Post-Radiation in Prostate Cancer - Praful Ravi
Beyond Medical Advancements: Addressing Financial and Personal Challenges in Metastatic Castration-Sensitive Prostate Cancer Treatment - Neeraj Agarwal
Combating Prostate Cancer: The Role of the NRG-GU-011 Study in Transforming Treatments - Bridget Koontz
TALAPRO-2 Study Reveals Efficacy and Tolerability of Talazoparib Combination for Prostate Cancer - Neeraj Agarwal
Exploring Darolutamide's Impact on Time to Pain Progression Based on Disease Volume in the ARASENS Study - Matthew Smith
Prostate Cancer Treatment Revolution: Radiotherapy and Abiraterone in the Spotlight of PEACE-1 - Alberto Bossi
Decoding Exceptional Responses: The National Cancer Institute's Unique Prostate Cancer Study - Fatima Karzai & Rana McKay
EMBARK Trial Shows Promising Results for High-Risk Prostate Cancer Treatment, Enzalutamide's Impact on Metastasis-Free Survival - Neal Shore
Improving Genetic Testing Rates in Advanced Prostate Cancer - Pedro Barata
DLL3 Targeting Bispecifics: A New Hope for Tough-to-Treat Prostate Cancer Patients - Rahul Aggarwal
Final Overall Survival Results from the PROpel Phase 3 Trial in First-line Therapy for mCRPC - Fred Saad
NCCN Guidelines: A Framework for PET Imaging Integration in Prostate Cancer Care - Edward Schaeffer
SPARE Trial's Implications for Prostate Cancer Patients - Carsten-Henning Ohlmann
Unveiling the Clinical Potential of ctDNA: Implications for Prostate Cancer Management - Neeraj Agarwal
Advances in Liquid Biopsies for Guiding Cancer Therapy - Jeffrey Ross
Geographic Variation in the Use of Doublet Therapy for Metastatic Prostate Cancer - Samuel Washington
Exploring the Molecular Mechanisms of Tumor Progression in Metastatic Prostate Cancer among Men of African Ancestry (MET-PAAM) - Clayton Yates
Developing a Blood-Based Biomarker Platform to Predict Treatment Outcomes in Prostate Cancer Patients - Martin Sjöström
Biomarker Analysis to Identify Molecular Signatures Predictive of Response in the COMBAT Study - Emmanuel Antonarakis
Contact-02: A Phase III Trial Shaping the Future of Metastatic Prostate Cancer Care - Neeraj Agarwal
Exploring the New Landscape of mCRPC: PARP Inhibitors, PSMA Radioligand Therapy, and More - Alicia Morgans
The AFT-19 Study: A Comprehensive Look at High-Risk Prostate Cancer Treatment - Rahul Aggarwal
The Promising Path of PSMA PET Imaging and Lutetium-177-PSMA in GU Oncology and Prostate Cancer Treatment - Susan Slovin
Exploring the SPLASH Trial: PSMA I&T Lutetium-177 in Pre-Chemo Metastatic CRPC - Oliver Sartor
Insights from the STAMPEDE Trial Platform - Marina Parry & Gerhardt Attard
CAR T and Cellular-Based Therapies - Vivek Narayan
Multidisciplinary Care for Patients, a Book Interview - Alicia Morgans
Biomarker-Directed Therapy in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Clara Hwang
The Future of Radiopharmaceuticals in the Treatment of Prostate Cancer - Philip Kantoff
Cancer Survivorship and PCF - Matthew Smith & Alicia Morgans
Timing and Intensity of ADT in Biochemical Recurrence - Channing J. Paller
When and How Much: A Deep Dive into the RADICALS Trial's Questions on Radiotherapy and Hormone Therapy - Nicholas James
An Ancillary Study of the STAMPEDE Trial Assessing the Clinical Qualification of Transcriptome Signatures for Advanced Prostate Cancer Starting ADT +/- Abiraterone Acetate and Prednisolone - Gerhardt Attard
From ADT to Triplet Therapy: Rethinking Treatment Paradigms in Metastatic Hormone Sensitive Prostate Cancer - Matthew Smith & Kim Chi
Impact of Histology Variants (Ductal/Intraductal/Cribriform) on Treatment Recommendation Presentation - Declan Murphy
Efficacy and Safety of 177Lu-PNT2002 PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer in the SPLASH - Neil Fleshner
Aggressive Variant Prostate Cancer: Definition, Diagnosis, Treatment APCCC 2022 Presentation - Eric Small
Emerging Therapies and Therapeutic Targets in Prostate Cancer - Mark Rubin
Immunotherapy and PARP Inhibitors in Biochemical Recurrent Prostate Cancer - Alexandra Sokolova
The 6th Global Summit On Precision Diagnosis and Treatment Of Prostate Cancer - Faina Shtern, The AdMe Tech Foundation
The EMBARK Study: A Phase 3 Randomized Study of Enzalutamide Plus Leuprolide and Enzalutamide Monotherapy in High-Risk Nonmetastatic Hormone-Sensitive Prostate Cancer with Rising PSA After Local Therapy - Stephen Freedland
The Efficacy and Safety of Relugolix versus Leuprolide in the HERO Study in Men with Advanced Prostate Cancer Based on Baseline BMI - Fred Saad
Optimizing the Use of Radium-223 Through Multidisciplinary Collaboration - Phillip Koo
Patient-Centric Approaches: The Urgent Need for Genetic Testing in Prostate Cancer - Brittany Szymaniak
Advancing Genetic Testing in Metastatic Prostate Cancer - Brenda Martone
Identifying the Right Patients for Treatment with Radium-223 for mCRPC - Brenda Martone
NCCN Guidelines Update on Selection of PSMA PET Imaging Agent in Patient Selection for Lutetium-177–PSMA-617 - Oliver Sartor
PARPi Combination Therapy Use in Clinical Practice - Ready for Prime-Time? - Maha Hussain and Fred Saad
Identifying Unmet Needs in the Patient Journey in Prostate Cancer - Alicia Morgans
The Management of High-Risk Localized Disease and Double Therapy in the mCRPC Setting - Andrey Soares
Lessons Learned in the STAMPEDE Trial - Nicholas James
Real-World Differences in Outcomes with First-Line Abiraterone Therapy Between African American and White Men with mCRPC - A UroToday Journal Club - Christopher Wallis & Zachary Klaassen
The Performance of a Genomic Classifier Score in the Phase 3 SAKK 09/10 in Patients with Biochemical Progression - Alan Dal Pra
Shared Decision-Making vs. Physician or Patient-Directed Decisions on Patient Quality of Life and Decision Satisfaction in Metastatic Prostate Cancer - Frank Schumacher
Clinical Trials in Progress: PSMA-Based Radioligand, 177Lu-PNT2002 For Men With Metastatic Castration-Resistant Prostate Cancer - The SPLASH Study - Neil Fleshner
Clinical Implementation of Pluvicto™ (177Lu-PSMA-617) - Michael Morris
The APCCC 2022 - A Hybrid Meeting April 28 - 30 - Silke Gillessen
The Risk of Prostate Cancer in Men with Inherited Germline TP53 Variants - Kara Maxwell
First Results of MAGNITUDE – Niraparib with Abiraterone Acetate and Prednisone a First-Line Therapy in Metastatic Castration-Resistant Prostate Cancer – Kim Chi
Risk Stratification in Metastatic Prostate Cancer: The Genomic Approach - Leanne Schimke
Do Our Treatments Drive a New Resistant Mutational Phenotype? - Ana Aparicio
COSMIC-021 Study: A Breakthrough in Metastatic CRPC Treatment with Cabozantinib and Atezolizumab - Neeraj Agarwal
Impact of Age on Castration Rates from The HERO Study – Michael Cookson
HERO Trial: Oral Relugolix for ADT in Advanced Prostate Cancer - Thomas Keane
Genomic Analysis and Assessment of Treatment Patterns To Better Understand Disparities in Advanced Prostate Cancer – Brandon Mahal
Ensuring Patients Have Access to Radium-223 as a Therapeutic Option: The DORA Trial - Michael Morris
Treatment Sequencing in Castrate-Resistant Metastatic Cancer - Mark Fleming
Relugolix in the Treatment of Advanced Prostate Cancer- Neeraj Agarwal
Selection of Androgen Deprivation Therapy for Use in Advanced Prostate Cancer - Bertrand Tombal
Assessment and Treatment of Cardiovascular Risk Factors in Veterans with Prostate Cancer - Ravi Parikh and Lova Sun
Metastasis-Directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer A UroToday Journal Club - Christopher Wallis & Zachary Klaassen
Advancing Knowledge About The Treatment of Advanced Prostate Cancer, Highlights from GU ASCO 2021 - Praful Ravi
Apalutamide Confirms Overall Survival Benefit at 44-Months in Metastatic Castration-Sensitive Prostate Cancer - The TITAN Study - Neeraj Agarwal
Patient Selection for ADT Treatment with the Oral GnRH Antagonist in Clinical Practice - Ashley Ross
Landscape of Circulating Tumor DNA Abnormalities in Advanced Prostate Cancer: Distinctions Between African-American and Caucasians - Pedro Barata
Cardiovascular Adverse Events and Comorbidity Considerations Disease in Men with Non-Metastatic Prostate Cancer - Christopher Wallis & Zachary Klaassen
Increased Risk for CV Disease in Men with Prostate Cancer - Alicia Morgans and Oliver Sartor
Transformations in the Treatments of Prostate Cancer - A Look at 2020 - Charles Ryan & Alicia Morgans
Disparities in Access to Quality Care for the Underinsured Patients in the USA - Quoc-Dien Trinh
The Progress and Promise of Prostate Cancer Treatments in 2020 - Charles Ryan & Alicia Morgans
Racial Differences in Genomic Profiling in Prostate Cancer - Brandon Mahal
Adjuvant or Early Salvage Radiotherapy for the Treatment of Localized and Locally Advanced Prostate Cancer - The ARTISTIC Collaborative Journal Club - Christopher Wallis ad Zachary Klaassen
A Prostate Cancer Community: Driving Access to Resources for Patients and Providers of Care - Felix Feng and Charles Ryan
Lower Odds of Cardiac Events for Gonadotropin Releasing Hormone Antagonists versus Agonists - Eugene Cone
The Oral GnRH Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant ADT to EBRT in Patients with Intermediate-risk Prostate Cancer - Thomas Keane
PROSPER Trial Journal Club: Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer - Zachary Klaassen and Christopher J.D. Wallis
Journal Club: Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer - Zachary Klaassen
HERO Phase III Trial: Results Comparing Relugolix, an Oral GnRH Receptor Antagonist Vs. Leuprolide Acetate for Advanced Prostate Cancer - Neal Shore
The Delivering of Genetic Counseling, Processes and Outcomes, The ProGen Study - Mary-Ellen Taplin
The Impact of Treatment Delays on Prostate Cancer During the COVID-19 Pandemic - Zach Klaassen & Chris Wallis
The Ethics of Delivering Precision Medicine — Hala Borno
Low Carbohydrate Diets in Men with Recurrent Prostate Cancer: The CAPS2 Study - Stephen Freedland
AR Indifferent Subtype Tumors in Prostate Cancer - Ana Aparicio
Supportive Therapy in Androgen Deprivation (STAND) - Rahul Aggarwal
Implementing Prostate Cancer Working Group 3 Criteria in Clinical Trials- Michael Morris and Lawrence Schwartz
Financial Toxicity and Quality of Life: Understanding and Improving Patient-Centered Outcomes in Genitourinary Malignancies - David Penson
Validation of a Prognostic Genomic Classifier in Salvage Radiotherapy Prostate Cancer from a Prospective Randomized Trial - Felix Feng
An Update on the PRONOUNCE Trial, Comparing the Occurrence of Major Adverse Cardiovascular Events in Patients with Prostate Cancer and Cardiovascular Disease - Susan Slovin
Understanding Differences in Outcomes of Men with Prostate Cancer Based on Race and Ethnicity - Christopher Logothetis
Precision Oncology Program for Cancer of the Prostate (POPCaP) - Matthew Rettig
Integrating PARP inhibitors into the Standard of Care for Prostate Cancer - Joaquin Mateo
The Changing Landscape for Locally Advanced Prostate Cancer- Maria de Santis
Imaging Modalities to Treat Node-Positive Disease - Interview with Declan Murphy
How to Treat Men with pN1 Prostate Cancer - Presentation - Alberto Bossi
Disadvantages of PSMA PET/CT in Advanced Prostate Cancer Imaging Presentation - Ian Davis
Radiation Therapy Options for Men with Newly Diagnosed cN1 cM0 Prostate Cancer - Mack Roach
How Best to Treat cN1 Prostate Cancer - Karim Fizazi
Ethnicity and Prognosis of Prostate Cancer - Christopher Logothetis
Testosterone Measurement – Which Test and When? - Martin Gleave
The Aging Population: Oncogeriatric Assessment and Treatment Considerations Presentation - Joe O'Sullivan
The Management of Sexuality and Incontinence in Advanced Prostate Cancer Presentation - Inge Van Oort
A Subgroup Analysis of mCRPC Clinical Trials Presentation - Susan Halabi
The Future of Advanced Prostate Cancer Management: In Locally Advanced Prostate Cancer Presentation - Alberto Briganti
The Best Use of Antiresorptive Therapy in CRPC Presentation - Matthew Smith
The Management of Fatigue, Cognition, and Dementia in Prostate Cancer Patients Presentation - Charles Ryan
Management of ADT Metabolic Complications: Assessment, Monitoring, Interventions Presentation - Neal Shore
The Future of Advanced Prostate Cancer Management: Access to Treatments Presentation - Karim Fizazi
The Future of APC Management in Polymetastatic Disease Presentation - William Oh
Which Systemic Therapy for Which Patient with Newly Diagnosed Metastatic Prostate Cancer Presentation - Chris Sweeney
Clinical Trial Treatment Options for Rare GU Malignancies - Bradley McGregor
Sinai Researchers Find First Mechanistic Link between World Trade Center Dust & Prostate Cancer - William Oh
APCCC 2019 Global vs. Expert Consensus in the Management of Advanced Prostate Cancer Study - Charles Ryan
Baseline PSA Level in Midlife and Aggressive Prostate Cancer in African American Men - Mark Preston
Optimizing Care in Localized Prostate Cancer - Mary-Ellen Taplin and Adam Kibel
Latin American Oncology Group (LACOG), a Cooperative Group Consensus - Fernando Maluf
Radiation Therapy Options for Prostate Cancer - Paul Nguyen
Ben Maughan Highlights Key Practice Changing Prostate Cancer Data
Genetic Counseling in Prostate Cancer - Brittany Szymaniak
Clinical Trials: Another Treatment Option for Patients - Tom Farrington
Molecular Genetic Testing in Prostate Cancer - Wassim Abida
Cognitive Function in Men with Prostate Cancer - Claire Pernar
Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines - Oliver Sartor
Biomarkers Across the Spectrum of Prostate Cancer- Anis Hamid and Chris Sweeney
Influence of BRCA-2 Mutations on the Natural History and Response to Therapy in Prostate Cancer- Elena Castro
Integrating Genomics into Localized Prostate Cancer - Todd Morgan and Daniel Spratt
Use of MRI to Risk Stratify Patients with Prostate Cancer- Simpa Salami
Current Landscape of Prostate Cancer Clinical Trials - Alliance Cooperative Group - Michael J. Morris
DNA Repair Defects in Metastatic Prostate Cancer - Elena Castro
Challenges in the Treatment of Localized Prostate Cancer - Srikala Sridhar
Optimizing ADT in Prostate Cancer Patients - Tom Keane
Effectiveness of Radical Prostatectomy with Adjuvant Radiotherapy versus Radiotherapy Plus ADT for Men with Advanced Prostate Cancer - Tom Keane
ENZADA, A Phase II Trial of Enzalutamide, Docetaxel, and Androgen Deprivation in Patients with Metastatic Hormone Sensitive Prostate Cancer - Earle Burgess
An Update on the PARP Inhibitor Olaparib in mCRPC Patients: Review of the Phase 2 Results & A First Look at the Phase 3 Study.
Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial - Fred Saad
TRIUMPH Study: Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations - Mark Markowski
Genetic Screening for Patients with Prostate Cancer - Todd Morgan
IRONMAN Registry: A Global Landmark Trial in Advanced Prostate Cancer
Prostate Cancer Awareness Month - David Penson
The Optimal Treatment for Gleason Score 9-10 Prostate Cancer - Daniel Spratt
The Role of the PARP Inhibitor in Treating Prostate Cancer: Interview with Joaquin Mateo
Androgen Receptor-Targeted Treatments for Prostate Cancer: 35 Years' Progress with Antiandrogens - E. David Crawford
Nuclear Medicine and Lutetium 177 PSMA Therapies - Carmel Pezaro
Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer (mCRPC) for Black versus White Men-Susan Halabi
Genetic Evaluation and Counseling in Prostate Cancer Treatment - Interview with Heather Cheng
Optimizing Care in Patients with High Risk Prostate Cancer - Interview with Edward Schaeffer
Use of Conservative Management for Low-Risk Prostate Cancer - Interview with Stacy Loeb
Long-Term Outcomes of Active Surveillance for Prostate Cancer - Interview with Sigrid Carlsson
Dedication to Multidisciplinary Management of GU Oncology - Alex Kutikov
Clinical Implications of the Abi Race Study: Interview with Dan George
Personalization of Therapy to Optimize Outcomes for Men with Prostate Cancer - Interview with Felix Feng
The Men’s Eating and Living (MEAL) Study, Diet Intervention in Men on Active Surveillance for Prostate Cancer - Interview with J. Kellogg Parsons
The RADICAL PC Project - Jehonathan Pinthus
Geriatric Assessment of Men with Prostate Cancer - Alicia Morgans
New Concepts in ADT- Thomas Keane
Quality of Life During Treatment with Chemohormonal Therapy - Alicia Morgans
Neoadjuvant Therapy for Men with High Risk Disease Prior to Prostatectomy - Mary-Ellen Taplin
Physician-Scientist Review Articles
State of the Evidence Review Articles
Written by Zachary Klaassen, MD, MSc Associate Professor of Urology Urologic Oncologist Medical College of Georgia, Georgia Cancer Center Augusta, GA & Rashid Sayyid, MD, MSc Urologic Oncology Fellow University of Toronto Toronto, Ontario, Canada
April 4, 2024
Given the promising results that Poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors have demonstrated for the treatment of metastatic castrate-resistant prostate cancer (mCRPC) patients who had progressed following prior androgen receptor pathway inhibitor (ARPI) and/or taxane-based chemotherapy
Written by Zachary Klaassen, MD, MSc Associate Professor of Urology Urologic Oncologist Medical College of Georgia, Georgia Cancer Center Augusta, GA and Rashid Sayyid, MD, MSc Urologic Oncology Fellow University of Toronto Toronto, Ontario, Canada
March 27, 2024
Poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors are drugs that prevent the repair of DNA single-stranded breaks and promote their conversion to double-stranded breaks resulting in a synthetic lethality.1 These drugs have demonstrated promising results for the treatment
Written by Rashid K. Sayyid, MD, MSc Urologic Oncology Fellow University of Toronto Toronto, ON and Zachary Klaassen, MD, MSc Associate Professor Wellstar MCG Health Augusta, GA
March 15, 2024
Over the past decade, there have been significant advances in defining the genomic landscape of prostate cancer. The landmark study by Pritchard et al. published in The New England Journal of Medicine in 2016 demonstrated that germline DNA-repair gene mutations were present in approximately
Written by Rashid K. Sayyid, MD MSc University of Toronto Toronto, ON & Zachary Klaassen, MD MSc Georgia Cancer Center Wellstar MCG Health Augusta, Georgia
November 8, 2023
Since the United States Food and Drug Administration (FDA) approval of mitoxantrone in 19961 and docetaxel in 20042 for the treatment of patients with metastatic castrate-resistant prostate cancer, we have witnessed the approval of numerous additional agents/combinations in this disease space:
Written by Rashid Sayyid, MD MSc University of Toronto Toronto, ON & Zachary Klaassen, MD MSc Georgia Cancer Center Wellstar MCG Health Augusta, GA
November 8, 2023

Introduction

There have been significant advances in the metastatic castrate-resistant prostate cancer (mCRPC) treatment landscape with the emergence and approval of numerous agents in this disease space.
Written by Rashid K. Sayyid, MD MSc & Zachary Klaassen, MD MSc
May 24, 2023

Introduction: Despite the approval of numerous agents in this setting, patients with metastatic castrate-resistant prostate cancer (mCRPC) have a poor prognosis, with an estimated median overall survival (OS) of approximately three years with currently approved first-line agents.1-3

Written by Zachary Klaassen, MD, MSc and Rashid K. Sayyid, MD, MSc
April 14, 2023

Artificial intelligence continues to transform the field of medicine, including the management of prostate cancer. In this Center of Excellence article, we discuss the contemporary literature evaluating artificial intelligence for risk stratification after primary therapy, ADT treatment intensification, and evaluation of metastatic disease.

Written by Rashid Sayyid, MD MSc & Zachary Klaassen, MD MSc
January 5, 2023

While external beam radiotherapy is a standard treatment option as first-line therapy for men with localized prostate cancer, it has been more recently recognized as an important component in the care of men with metastatic prostate cancer. This Center of Excellence article will explore recent evidence for the utilization of radiotherapy in the metastatic setting.

Written by Rashid Sayyid, MD MSc, & Zachary Klaassen, MD MSc
October 19, 2022
While PSMA PET/CT is currently FDA approved for the initial staging of patients with presumed localized, high-risk prostate cancer and for the diagnostic work up of patients with biochemical failure following primary treatment, the role of PSMA PET/CT in patients with known metastatic prostate cancer is not as well-defined.
Written by Rashid Sayyid, MD, MSc, & Zachary Klaassen, MD, MSc
September 7, 2022
While there have been clear survival benefits for patients with metastatic castration resistant prostate cancer (mCRPC) with the use of taxane chemotherapy and novel androgen receptor targeting agents, most patients eventually progress following these treatments.
Written by Rashid Sayyid, MD MSc, & Zachary Klaassen, MD MSc
September 7, 2022
Radiopharmaceuticals are pharmaceutical agents which contain radioisotopes that emit radiation, which may be used for diagnostic or treatment purposes. Historically, beta-particle emitting agents including strontium-89 (Metastron), samarium-153 (Quadramet), phosphorus-32, and rhenium-186 were used as palliative therapies for patients with symptomatic bone disease.
Written by Rashid Sayyid, MD MSc, & Zachary Klaassen, MD MSc
September 6, 2022

While the emergence of castration resistant disease comes as a result of the disease progressing in spite of castrate levels of testosterone (at times called hormone refractory disease), prostate cancer (even in the castration resistance prostate cancer (CRPC) setting) remains heavily dependent on the androgen axis.

Written by Zachary Klaassen, MD MSc and Rashid Sayyid, MD MSc
August 30, 2022

Prostate cancer, while commonly diagnosed as localized disease, remains the second leading cause of cancer mortality in the United States and Europe.1 For patients who die of prostate cancer, some will be initially diagnosed and treated for metastatic hormone-sensitive disease (mHSPC).

Written by Zachary Klaassen, MD, MSc
July 2, 2020
Prostate cancer is a clinically heterogeneous disease with many patients having an indolent course requiring no interventions and others who either present with or progress to metastasis. While underlying dominant driving mutations are not widespread, there have been a number of key genomic mutations that have been consistently identified in prostate cancer patients,
Written by Zachary Klaassen, MD, MSc
May 14, 2020
The coronavirus has the potential to impact the integrity and patient safety of ongoing trials as well as increase the operational burden on trial programs, therefore potentially limiting access to trials and new therapies for oncology patients. Opportunities for clinical trial enrollment may still be provided to patients during the COVID-19 outbreak, but likely require thorough evaluation on a case-by-case basis.
Written by Zachary Klaassen, MD, MSc
December 10, 2019

Despite prostate cancer (PCa) being the second most common cause of cancer mortality among American men,1 there are 2.9 million men in the United States living with PCa. As such, there are many “PCa survivors” that are either on active surveillance (AS)/watchful waiting (WW) or have undergone treatment for localized (ie. radiation therapy (RT), radical prostatectomy (RP), focal therapy, etc) or advanced disease. 

Written by Zachary Klaassen, MD, MSc
December 18, 2019

Understanding and elucidating the underlying genetic basis of carcinogenesis has been the holy grail for cancer researchers, for both the scientific understanding of disease pathophysiology and potential therapeutic implications. Perhaps the best example of the therapeutic implications of understanding carcinogenesis come from chronic myeloid leukemia where the identification of the “Philadelphia chromosome”;

Written by Zachary Klaassen, MD, MSc
November 15, 2019
Despite the exciting advances in treatment over the last decade for metastatic castration-resistant prostate cancer (mCRPC), the disease remains incurable with a median overall survival of 12-35 months.1-4 Targeting the immune system to expand treatment options in the advanced disease state has resulted in significant improvements
Written by Hanan Goldberg, MD
December 10, 2019
In 2018 1.3 million prostate cancer (PCa) cases were diagnosed worldwide, with approximately 20% having metastatic disease.1 Oligometastatic PCa is defined as a state of low-volume metastatic disease that appears to be prognostically different and likely amenable to different treatment options, which could potentially change the disease trajectory when compared with high-volume metastatic disease.2
Written by Zachary Klaassen, MD, MSc
April 16, 2019
In 2018 in the United States, there will be an estimated 164,690 new cases of prostate cancer (19% of all male cancer incident cases, 1st) and an estimated 29,430 prostate cancer mortalities (9% of all male cancer deaths, 2nd only to lung/bronchus cancer).1 Over the last four decades, there was a spike
Written by Zachary Klaassen, MD, MSc
April 16, 2019
The discovery of prostate-specific antigen (PSA) in the late 1970s and its widespread application and adoption in the 1980s and 1990s ushered in the prostate cancer screening and disease monitoring era. As the first tumor marker for prostate cancer, it is organ specific but not cancer specific.1
Physician-Scientist Commentaries
Peer-reviewed Abstract Supplemental Commentaries
Written by Christopher Wallis, MD, PhD, FRCSC, Assistant Professor, Division of Urology, University of Toronto
Beginning with the data from TAX-327 demonstrating the overall survival advantage of docetaxel in men with metastatic castration-resistant prostate cancer (mCRPC), this disease space has gone from one of the repeated dead-ends to a flourishing research field with many agents gaining approval over the last 15 years as a result of demonstrated survival benefits.
Conference Coverage
Conference Highlights Written by Physician-Scientist
Presented by Ruth E. Langley, PhD
The 2024 ESMO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Ruth Langley discussing efficacy results from a randomized phase 3 evaluation of transdermal estradiol versus luteinizing hormone-releasing hormone (LHRH) agonists for androgen suppression in M0 prostate cancer.
Presented by Irene Burger, MD
The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13th and 16th, 2024 was host to a proffered paper session for prostate cancer. Professor Irene Burger provided the discussant for both SPLASH and UpFrontPSMA.
Presented by Elena Castro, MD, PhD
The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to the session Therapeutic options beyond AR pathway inhibitors: What do we choose next? Dr. Elena Castro discussed if cytotoxics are still the next option after ARPIs.
Presented by Karim Fizazi, MD, PhD
The 2024 ASCO featured a session on prostate cancer, and a presentation by Dr. Karim Fizazi discussing results from PSMAfore, specifically health-related quality of life and pain among taxane-naïve metastatic castration-resistant prostate cancer (mCRPC) patients treated with 177Lu-PSMA-617. 
Presented by  Christos Kyriakopoulos, MD
The 2024 ASCO annual meeting featured an oral abstract session on prostate cancer, and a presentation by Dr. Christos Kyriakopoulos discussing results of the CHAARTED2 trial assessing cabazitaxel with abiraterone versus abiraterone alone for extensive disease following docetaxel.
Presented by Matthew R. Smith, MD, PhD
The 2024 American Society of Clinical Oncology (ASCO) annual meeting featured a session on prostate cancer, and a presentation by Dr. Matthew Smith discussing results of CYCLONE 2, a phase 3 trial assessing abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC). Oncogenic addiction to androgen receptor signaling drives mCRPC progression, highlighting the unmet need for novel treatment strategies to maximize androgen receptor-directed therapy.
Presented by Geoffrey Johnson, MD, PhD
During the 2024 ASCO GU cancers symposium, Dr. Geoffrey Johnson presented the study framework of SECuRE, a dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate-resistant prostate cancer (mCRPC).
Presented by Maha Hussain, MD
Maha Hussain discussing BRCAAway, a randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair (HRR) mutations.  
Presented by Neeraj Agarwal, MD
Neeraj Agarwal presented CONTACT-2, a phase 3 study of cabozantinib + atezolizumab vs second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
Presented by Karim Fizazi, MD, PhD
Dr. Karim Fizazi presented the results of CYPIDES, a phase 2 trial evaluating MK-5684 (ODM-208), a CYP11A1 inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) with and without androgen receptor (AR) ligand binding domain (LBD) mutations.
Presented by Oliver Sartor, MD
Oliver Sartor presented the safety outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 following external beam radiation therapy in the REASSURE study.
Presented by Daniel Y. Song, MD
The 2023 ASCO annual meeting included a prostate cancer session, featuring a presentation by Dr. Daniel Song discussing the REASSURE study assessing real-world safety and effectiveness of Radium-223 in patients with metastatic castration-resistant prostate cancer (mCRPC) treated in the US. Radium-223 improved overall survival and quality of life and demonstrated a favorable safety profile in patients with mCRPC in the phase 3 ALSYMPCA trial.
Presented by Joaquin Mateo, MD, PhD
At the 2023 ASCO annual meeting Dr. Mateo discussed two abstracts including “PANTHER: A prospective trial of apalutamide and abiraterone acetate plus prednisone in Black and White men with mCRPC” presented by Dr. Daniel George, and “STARTAR: A phase 2 salvage trial of androgen receptor inhibition with ADT and apalutamide with radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer after radical prostatectomy” presented by Dr. Tian Zhang.
Presented by Ravi Amrit Madan, MD
In the discussant presentation at the 2023 ASCO annual meeting Dr. Ravi Madan discussed quality in the context of quantity: evaluating treatment intensification. He discussed three abstracts presented in this session:
Presented by Neeraj Agarwal, MD, FASCO
TALAPRO-2 is a phase III study evaluating the combination of the poly (ADP-ribose) polymerase inhibitor talazoparib and enzalutamide versus enzalutamide and placebo as first-line treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). It exists in the landscape of sequential and advancing studies of PARP inhibitors (PARPi) in prostate cancer.
Presented by Ana Aparicio, MD
The second Prostate Cancer Session of the Annual Meeting of the Society of Urologic Oncology was held on Friday, December 2nd, 2022. In this session, Dr. Ana Aparicio presented on the role of biomarkers and somatic testing to guide treatment choice in advanced prostate cancer.
Presented by Samuel L. Washington III, MD, MAS
The 23rd Annual Meeting of the SUO was host to a prostate cancer session. Dr. Samuel L. Washington III, MD, MAS presented the results of a population-based analysis evaluating geographic variations in the utilization of doublet therapy for metastatic prostate cancer patients.
Presented by Fred Saad, MD, FRCS
The 2022 ESMO annual meeting featured a prostate cancer session, including a presentation by Dr. Fred Saad discussing a biomarker analysis and updated results from the Phase III PROpel trial of abiraterone and olaparib vs abiraterone and placebo as first-line therapy for patients with mCRPC.
Presented by Michael S. Cookson, MD, MMHC
In a podium presentation in the Prostate cancer IV - Advanced disease session at the 19th Meeting of the EAU Section of Oncological Urology, Dr. Cookson presented on the changing face of prostate cancer, with important implications for our practice of evidence-based medicine.
Presented by William Thomas Lowrance, MD, MPH, MBA
In this plenary session, Dr. William Thomas Lowrance summarized the 2021 AUA/ASTRO/SUO guidelines on advanced prostate cancer, with key take-home points highlighted. The full 2 part guidelines1,2 can be found online at They are also published in the Journal of Urology.
Presented by Stephen A. Boorjian, MD
The Society of Urologic Oncology held an associated session at the American Urologic Association Virtual Annual Meeting entitled “The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion.” Dr. Stephen Boorjian began this session with a talk focusing on the identification of patients with high-risk prostate cancer and the initial management of those with biochemical recurrence following therapy.
Presented by Michael Cookson, MD, MMHC
As the therapeutic landscape evolves to include increasingly complex combinations of systemic therapies with or without local therapies, advances in imaging, and germline and somatic testing, treating men with advanced prostate cancer is increasingly one that must embrace multidisciplinary management approaches.
Presented by Neal D. Shore, MD, FACS, and Ashley Evan Ross MD, PhD
During the second prostate cancer session at the 2020 Annual Meeting of the Society of Urologic Oncology (SUO), Drs. Neal Shore and Ashley Evan Ross debated the use of relugolix as a new standard of care for androgen deprivation therapy (ADT) for the treatment of prostate cancer.
Presented by Reham Alghandour, PhD
Metformin is a biguanide agent which is commonly used in the first-line treatment of patients with type 2 diabetes. For many years, there has been an interest in its potential anti-cancer properties, particularly in prostate cancer.
Presented by William T. Lowrance, MD, MPH
The AUA 2020 virtual annual meeting was highlighted by an update on the AUA guidelines for advanced prostate cancer, presented by Dr. William Lowrance and Dr. Michael Cookson. Dr. Lowrance notes that this guideline was produced by a multidisciplinary panel with representation from the AUA, ASCO, ASTRO, and SUO was well as a patient advocate.
Presented by Elena Castro, MD, PhD
San Francisco, CA (UroToday.com) In this talk, Dr. Elena Castro gave an overview of the genomic landscape of advanced prostate cancer. It has been shown that in over 70%
Presented by Samuel Denmeade
Washington, DC (UroToday.com) As part of the SUO 2019 advanced prostate cancer session, Dr. Samuel Denmeade discussed his work with bipolar androgen therapy (BAT)
Presented by Samuel Denmeade, MD
Washington, DC (UroToday.com)  Since Huggins’ noble prize-winning work on the role of androgens in prostate cancer progression in 1940, hormonal suppression has been the mainstay
Presented by Kelly Stratton, MD
Athens, Greece (UroToday.com) Dr. Kelly Stratton gave an overview of the role of surgery in advanced prostate cancer. Advanced prostate cancer 
Presented by Derya Tilki, MD
Athens, Greece (UroToday.com) Dr. Derya Tilki was the first to present at the Educating Masterclass on Biochemical Recurrence after Radical Prostatectomy.
Presented by Karim Fizazi, MD, PhD
Barcelona, Spain (UroToday.com) At the Friday session at the 2019 European Society for Medical Oncology annual meeting (ESMO) meeting on prostate cancer, Karim Fizazi
Presented by Maria J. Ribal, MD
Barcelona, Spain (UroToday.com) Dr. Maria Ribal from Barcelona started the urogenital cancer treatment at a glance session by giving an overview of challenging paradigms in advanced prostate cancer. Dr. Ribal notes that not only is the incidence of prostate cancer the highest among male malignancies,
Presented by Himisha Beltran, MD
San Francisco, CA (UroToday.com) Dr. Misha Beltran presented a summary of the biologic basis for sequencing novel treatments for metastatic prostate cancer.  There is an increasing need for biomarkers in advanced prostate cancer management
Presented by Srikala S. Sridhar, MD, FRCPC, Alberto Briganti, MD, PhD, and Heather Ann Payne, MBBS, FRCP, FRCR
San Francisco, CA (UroToday.com) During the general session on optimizing diagnosis and treatment of clinically significant nonmetastatic prostate cancer at the Annual ASCO GU 2019 meeting
Presented by Kim Chi, MD
Phoenix, Arizona (UroToday.com) The LATITUDE study, published in July 2017, was a phase III randomized, clinical trial that evaluated the efficacy of abiraterone 
Presented by Laurence Klotz, MD
Tel-Aviv, Israel (UroToday.com) Laurence Klotz, MD gave a presentation on intermittent androgen deprivation therapy (IADT) and its association with cardiovascular disease (CVD). He began stating the many advantages of intermittent androgen deprivation therapy.
Presented by Jehonathan Pinthus, MD
Tel-Aviv, Israel (UroToday.com) Jehonathan Pinthus, MD presented the RADICAL PC trial and elaborated on the correlation of prostate cancer (PC) to cardiovascular disease (CVD). It is known that PC patients are at risk for CVD. Patients are deemed to be high-risk if they have a global risk estimate for severe CVD events with a rate of more than 2% per year.
Presented by Silke Gillessen, MD
Copenhagen, Denmark (UroToday.com)  Dr. Sommer gave an overview of the complications associated with the treatment for advanced prostate cancer. The first topic discussed was the acute side effects of androgen deprivation therapy (ADT). These include decreased libido, erectile dysfunction, hot flashes, and fatigue.
Presented by Karim Fizazi, MD, PhD
Chicago, IL (UroToday.com) Dr. Karim Fizazi and colleagues presented their much-anticipated results from the LATITUDE trial at the 2017 ASCO annual meeting’s plenary session. In a phase III, double-blind, randomized setting, LATITUDE tested androgen deprivation therapy